STOCK TITAN

Sanitam Partners LLC (MTNB) distributes Matinas BioPharma stake and ends beneficial ownership

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Sanitam Partners LLC, a more than ten percent owner of Matinas BioPharma Holdings, Inc., reported restructuring transactions dated June 10, 2026. It disposed of Series C Convertible Preferred Stock and warrants through a distribution of its holdings to its members. Following these transactions, Sanitam no longer beneficially owns any securities of Matinas BioPharma.

Positive

  • None.

Negative

  • None.
Insider Sanitam Partners LLC
Role 10% Owner
Type Security Shares Price Value
Other Series C Convertible Preferred Stock F1, F2 1,406 $0.586 $823.92
Other Warrants to Purchase Common Stock F1 4,798,636 $0.6446 $3.09M
Holdings After Transaction: Series C Convertible Preferred Stock — 0 shares (Direct); Warrants to Purchase Common Stock — 0 shares (Direct)
Footnotes (2)
  1. F1. On June 10, 2026, Sanitam Parnters LLC ("Sanitam") distributed its holdings in the Registrant's preferred stock and warrants to its members. As such Sanitam no longer beneficially owns any securities of the Registrant.
  2. F2. The Series C Convertible Preferred Stock of the Registrant is perpetual and has no expiration date.
Series C Preferred Shares Disposed 1,406 shares Series C Convertible Preferred Stock reported as disposed on June 10, 2026
Preferred Conversion Price $0.5860 per share Conversion or exercise price of Series C Convertible Preferred Stock
Underlying Common from Preferred 2,399,318 shares Common Stock underlying the Series C Convertible Preferred Stock position
Warrants Disposed 4,798,636 warrants Warrants to Purchase Common Stock reported as disposed on June 10, 2026
Warrant Exercise Price $0.6446 per share Conversion or exercise price of the Warrants to Purchase Common Stock
Warrant Expiration April 8, 2030 Expiration date of the Warrants to Purchase Common Stock
Restructuring Shares Total 4,800,042 shares Total restructuring-related shares in transaction summary
Post-Transaction Holdings 0 securities Total securities beneficially owned by Sanitam after distribution
Series C Convertible Preferred Stock financial
"security title listed as Series C Convertible Preferred Stock"
Series C convertible preferred stock is a class of investment shares issued in a later private financing round that combine safety and upside: they usually pay ahead of ordinary shares if a company pays dividends or is sold, but can be converted into common stock to share in future growth. For investors this acts like a VIP ticket with a safety net—offering priority protection while preserving the option to participate in a successful exit.
Warrants to Purchase Common Stock financial
"security title listed as Warrants to Purchase Common Stock"
beneficially owns financial
"Sanitam no longer beneficially owns any securities of the Registrant"
Beneficially owns means a person or entity enjoys the economic benefits and control of a security even if the legal title or registration is held in another name. Think of it like having the keys and profits from a car that is registered to a friend: you use it, benefit from it, and make decisions about it even though the official paperwork lists someone else. For investors, this matters because it reveals who truly controls shares, affects voting power, potential conflicts of interest, and regulatory disclosure obligations.
other acquisition or disposition financial
"transaction code J described as Other acquisition or disposition"
perpetual financial
"The Series C Convertible Preferred Stock of the Registrant is perpetual"
Perpetual describes a financial instrument or obligation that has no fixed end date and can continue indefinitely unless the issuer chooses to end it. For investors, that means there is no scheduled return of principal, so value depends on ongoing payments, issuer stability and market interest rates—similar to receiving rent from a property with no set sale date. Perpetual instruments often pay higher yields to compensate for that open-ended risk.

FAQ

What did Sanitam Partners LLC report in its Form 4 for MTNB?

Sanitam Partners LLC reported dispositions of Series C Convertible Preferred Stock and warrants on June 10, 2026 as part of an internal restructuring distribution to its members.

How many shares of MTNB preferred stock were involved in the Sanitam Partners LLC transaction?

The transaction covered 1,406 shares of Series C Convertible Preferred Stock, which were convertible into 2,399,318 shares of Matinas BioPharma common stock before the restructuring distribution.

What warrants of MTNB were affected in the Sanitam Partners LLC filing?

Sanitam Partners LLC disposed of 4,798,636 Warrants to Purchase Common Stock, each with a conversion or exercise price of $0.6446 per share and an expiration date of April 8, 2030.

Does Sanitam Partners LLC still beneficially own MTNB securities after this Form 4?

No. The filing states that after distributing its preferred stock and warrants to its members, Sanitam no longer beneficially owns any securities of Matinas BioPharma Holdings, Inc.

Was the MTNB Form 4 transaction a market sale or an internal transfer?

The Form 4 describes an internal distribution of preferred stock and warrants by Sanitam Partners LLC to its members, coded as an “other acquisition or disposition” (J), not a market purchase or sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
X
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Sanitam Partners LLC

(Last)(First)(Middle)
888 C 8TH AVE #530

(Street)
NEW YORK NEW YORK 10019

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Matinas BioPharma Holdings, Inc. [ MTNB ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
DirectorX10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Series C Convertible Preferred Stock$0.58606/10/2026J(1)1,40604/04/2025 (2)Common Stock2,399,318$0.5860D
Warrants to Purchase Common Stock$0.644606/10/2026J(1)4,798,63604/08/202504/08/2030Common Stock4,798,636$0.64460D
Explanation of Responses:
1. On June 10, 2026, Sanitam Parnters LLC ("Sanitam") distributed its holdings in the Registrant's preferred stock and warrants to its members. As such Sanitam no longer beneficially owns any securities of the Registrant.
2. The Series C Convertible Preferred Stock of the Registrant is perpetual and has no expiration date.
/s/ Adam Stern, Managing Member of Sanitam Partners LLC08/13/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)